Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

My name is Kate and I will be your conference operator today. At this time, I would like to welcome everyone to the Q4 2024 series Therapeutics Incorporated Earnings Conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed with the number one on your telephone keypad. If you would like to withdraw your question, press star 1 again. Thank you. I would now like to turn the call over to Carlo Tanzi of Investor Relations. Please go ahead. Thank you and good morning. Our press release with the company's fourth quarter and full year 2024 financial results and business updates became available at 7 a.m. Eastern Time this morning and can be found on the Investors & News section of the company's website. The company has also posted an updated corporate presentation to the website. I'd like to remind you that we'll be making forward-looking statements, including statements about the timing and results of our clinical studies and data readouts, future product candidates, clinical development plans and commercial opportunities, interactions with regulatory agencies, receipt of future payments related to the valve sale, operating plans and future cash runway, our ability to generate additional capital, our planned strategic focus, our efforts to secure partnerships, and anticipated timing of any of the foregoing and other statements which are not historical fact. Actual results may differ materially. Additionally, these statements are subject to certain risks and uncertainties, which are discussed under the risk factors section of our recent SEC filings. Any forward-looking statements made on today's...